ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. Here you will find a summary of ICON plc's latest financial information. We are also delighted to announce the extension of ICONâs master services agreement with Pfizer. System1 Group PLC Financial Information, disclosed in accordance with Rule 26 of the AIM Rules 2019 outlook reaffirmed with revenue guidance in the range of $2,735 - $2,835 million and earnings per share guidance in the range of $6.69 â $6.89 a year over year increase of 9.9% - 13.1%.Â. Telecom Plus PLC trades as UW (Utility Warehouse) and is trusted by over 650,000 households and small businesses nationwide. ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, ... Information about the directors and executive officers of ICON is set forth in its annual report on Form 20-F, which was filed with the SEC on February 27, 2020. We have extensive experience in a broad range of therapeutic areas. Reported earnings per share on a diluted basis was $1.62. With headquarters in Dublin, Ireland, ICON employed approximately 13,670 employees in 89 locations in 37 countries as at December 31, 2018. BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON to acquire PRA Health Sciences. 0001060955-20-000004.rtf. ICON plc 2014 20F 2.4 MB. ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. Investor Relations Analyst. Full year reported revenue of $2,596 million. Record closing backlog of $8.7 billion , an increase of 10.4% year on year. ICON plc. Backlog of business grows 8.6% year on year to surpass $4 billion for the first time. ICON plc to Present at the 39th Annual JP Morgan Healthcare Conference. Read the consolidated income statements and summary balance sheet data. Regulatory news Keep up to date with our RNS Regulatory news Full year reported revenue was $2,595.8 million. … 24 Feb Reported income from operations in the quarter was $101.8 million or 15.0% of revenue. Full year reported income from operations before non-recurring charges was $385.8 million or 14.9% of revenue. Quarter 2 reported revenue of $641.6 million . 0001060955-20-000004.pdf. With headquarters in Dublin, Ireland, ICON currently operates from 94 locations in 40 countries and has approximately 15,150 employees as of June 30, 2020. ICON plc 2014 IFRS Annual Report. Title Type; ICON Reports Fourth Quarter and Full Year 2020 Results. ICON plc 2015 20-F. ICON plc 2015 20-F 757.8 KB. Annual Reports Championing the Specialist Read about the Group's latest business developments and financial highlights, and learn more about our markets, brands and colleagues in the Informa 2019 Annual Report, Championing the Specialist . ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. Cash generated from operating activities for the quarter was $60.9 million. Form Filing date View; 20-F: February 27, 2020: View HTML. ICON plc 2015 IFRS Annual Report 588.1 KB. This resulted in net business wins of $607 million, a book to bill of 1.25. Full year reported income from operations before non-recurring charges was $385.8 million or 14.9% of revenue. Deal creates a world leader in healthcare intelligence and clinical research. ICON Releases First Environmental, Social and Governance Report. Today we are delighted to announce the acquisition of MolecularMD. Title. Excluding the impact of ASC 606, diluted earnings per share before non-recurring charges increased by 14.2% to $6.16, compared to $5.39 per share last year. Financial statements and reports for Iconic Labs plc (ICON) Ord GBP0.0025 including annual reports and financial results for the last 5 years. Linkedin social media brand icon. Vaccines. Countrywide plc Annual Report 2018; Full year results. You are: (A) not located in the United States and are not resident in or located in Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction where … Title Type; ICON Reports Third Quarter 2020 Results . The Investor Relations website contains information about ICON plc's business for stockholders, potential investors, and financial analysts. Record net business wins* in the quarter of $607 million, a book to bill of 1.25. The principal activity of ICON plc ("the Company") is to act as a holding Company. Get the detailed quarterly/annual income statement for ICON plc (ICLR). Our mission is to help clients accelerate the development of ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. Serving governments, multinational public health organisations, and global NGOs. Annual Report. Reported net income for the quarter was $88.2 million or 13.0% of revenue. Our full report and accounts for the year ended 31 March 2020. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas , and can be adapted to suit small local trials or large global programs. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. Published on Oct 28, 2020. ICON plc IFRS Annual Report 2013. Countrywide plc is registered in England under number 08340090. Income from operations increases 14.5% to $78 million , before During the quarter, capital expenditure was $20.0 million and $72 million worth of stock was repurchased at an average price of $137.66. Quarter 1 reported revenue of $715.1 million representing a 6.0% year on year increase or 6.5% on a constant currency basis. 0001060955-21-000004.pdf. Date. A roadmap to meet 2022 deadlines, while navigating pandemic disruptions. . Registered office: Greenwood House, 1st Floor, 91-99 New London Road, Chelmsford, Essex, CM2 0PP. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. development and commercialisation, and can be adapted to This press release contains forward-looking statements. Highlights Excluding the impact of ASC 606, record net business wins in the quarter of $600 million ; a book to bill of 1.27. The Investor Relations website contains information about ICON plc's business for stockholders, potential investors, and financial analysts. MolecularMDâs services also include companion diagnostic development which will further enhance the competitiveness of our overall lab offering. Reported revenue for quarter 4 was $679.0 million. Leopardstown. ICON plc and SubsidiariesAnnual Report 2017 1 Contents Directors’ and Other Information 2 Directors’ Report 3 Statement of Directors’ Responsibilities in respect of the Directors’ report and the financial statements 12 03/07/2019. Our services span the entire lifecycle of product Full year reported net income before non-recurring charges was $333.7 million or 12.9% of revenue. Earnings Release. Excluding the impact of ASC 606, net income before non-recurring charges increased by 14.1% to $337.4 million, compared with $295.7 million last year. Full year reported earnings per share before non-recurring charges of $6.09. This represents an increase* for the quarter and full year of 13.8% and 14.2% respectively. We are currently working on a number of COVID-19 vaccine trials. Contact: Investor Relations +1888 381 7923 or The cumulative effect of initially applying the new standard is reflected as an adjustment to opening equity at the date of application. Results for the three and twelve months ended December 2017 are therefore presented under the previous revenue recognition accounting principles.Â. Excluding the impact of ASC 606, income from operations before non-recurring charges increased by 12.7% to $390.0 million, or 20.6% of revenue, compared to $346.1 million or 19.7% of revenue in the previous year. ICON plc IFRS 2019 2 MB. Get by Email • RSS. As a result, at December 31, 2018, the company had net cash of $106.5 million, compared to net cash of $142.3 million at September 30, 2018 and net cash of $11.6 million at the end of December 2017.Â. Carnival Corporation & plc Annual Reports. Creating a world leader in healthcare intelligence and clinical research. About us ... FY20 annual report and accounts. ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards. Full year net business wins of $3.8 billion; a net book to bill of 1.38. ICON plc | Clinical Research Organisation (CRO) for Drug Development. ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the worldâs leading Contract Research Organisations through a number of high-profile industry awards. The extension of the agreement reflects our strong working relationship with Pfizer and we look forward to continuing to help Pfizer advance its development pipeline rapidly and efficiently. Connecting patients with the right trial in the right location. ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. ICON plc 2014 20F. suit small local trials or large global programs. ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial. Excluding the impact of ASC 606, quarter 4 revenue increased to $484.7 million from $455.1 million in the same quarter last year, an increase of 6.5%. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. The promise and complexity of living therapies. 02/26/2020. Elizabeth Denham has published her fourth annual report as the UK's Information Commissioner. Further information is available at www.iconplc.com. The Company also operates branch Highlights Net business wins in the quarter of $867 million ; a book to bill of 1.21. Excluding the impact of ASC 606, diluted earnings per share increased by 13.8% to $1.63, compared to $1.43 per share for the same quarter last year. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov. Excluding the impact of ASC 606, full year revenue increased to $1,897.6 million from $1,758.4 million in 2017, an increase of 7.9%. Quarter 4 reported income from operations was $101.8 million, or 15.0% of revenue. ICON provides analysis and key insights on these challenges, with practical advice and recommendations. Dublin 18. 11 November, 2020. Carnival Corporation & plc 2019 Annual Report 614.9 KB. Ireland. Bringing the clinical trial to the patient with innovation and in-home solutions. The extension of ICONâs master services agreement with Pfizer Inc. (NYSE:PFE). Earnings Release. The new revenue recognition standard (ASU No. Annual report 2019-20. Quarter 4 reported earnings per share of $1.62. ICON provides its full range of clinical, consulting and commercial services across several industry sectors. ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. Full year reported revenue of $2,797 million representing a 0.3% year on year decrease. ICON plc IFRS Annual Report 2013 752.2 KB. Annual Report 2017 ICON plc and Subsidiaries. Jonathan Curtain, Vice President Corporate Finance and Investor Relations +1 215 616 3000, Decentralised & hybrid clinical solutions, Webinar: Transforming CNS drug development with wet lab and imaging biomarker solutions, income statements and summary balance sheet data, ICON Reports Fourth Quarter and Full Year 2018 Results. Excluding the impact of ASC 606, income from operations increased by 14.2% to $102.4 million, or 21.1% of revenue, compared to $89.7 million or 19.7% for the same quarter last year. We develop integrated technologies to significantly enhance the efficiency and productivity of clientsâ drug and device development programs. Excluding the impact of ASC 606, gross business wins in the fourth quarter were $722 million and cancellations were $115 million. Results, reports and presentations. Excluding the impact of ASC 606, closing backlog of $5.2 billion , an increase of 16% year on year. Our objective is to deliver sustainable, quality returns on behalf of our shareholders by providing products and services to a diverse range of end markets including rail, transmission, water, civil engineering, construction, house building, oil and gas. Read the eBook. 30 October, 2020. ICON Plc Annual Reports News Monitoring. ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. Patient focused research for better outcomes. On publishing the report Ms Denham said: “We have seen a transformative period in our digital history, with privacy established as a mainstream concern, and with complex societal conversations increasingly asking data protection questions. Form Filing date View; 20-F: February 24, 2021: View HTML. Tel (INTL. Through our award winning website, partnerships, and our vast network of institutional & individual investors, AnnualReports.com will expand your reach to the serious investor. ICON will hold its fourth quarter conference call tomorrow, February 21st, 2019 at 09:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under âInvestorsâ. This calendar will be updated regularly. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. Icon Plc (ICLR) SEC Filing 20-F Annual report for the fiscal year ending Tuesday, December 31, 2019 ICON plc 2014 IFRS Annual Report 2.3 MB. ICON plc has reached its limit for free report views. Net revenue increases 5.7% to $411 million in the quarter. Investors. MolecularMD enhances our laboratory offering in molecular diagnostic testing, a key area in oncology research, and also brings to ICON expanded testing platforms, including next generation sequencing and immunohistochemistry. South County Business Park. Read more. CEO Dr. Steve Cutler commented, âDuring 2018, ICONâs operational excellence and market leading service offerings resulted in net business bookings of over $2.4 billion and the expansion of our backlog by 10% to $5.4 billion. Managing studies in all major geographies, we have established solid working relationships with the worldâs leading investigators. Carnival Corporation & plc 2018 Annual Report 748.1 KB. Questions for the Investor Relations Department can be submitted through the form below. Excluding the impact of ASC 606, full year revenue increased to $1,897.6 million from $1,758.4 million in 2017, an increase of 7.9%. ICON Reports Fourth Quarter and Full Year 2020 Results 115.2 KB.